Rest Of Europe Cell Isolation Market (2026-2031)
The Rest Of Europe Cell Isolation Market was valued at $120.2 Million in 2026 and projected to reach to $184.9 Million by 2031, representing a compound annual growth rate of 9.0%. Rest Of Europe's cell isolation market demonstrates steady expansion driven by growing research activities and clinical applications across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe Cell Isolation Market Trends and Insights
- This 9.0% compound annual growth rate reflects increasing adoption of advanced cell isolation technologies across research institutions, clinical laboratories, and biopharmaceutical companies throughout the region.
- Rest Of Europe is benefiting from rising investments in regenerative medicine, cell therapy development, and personalized medicine initiatives that drive demand for sophisticated isolation and purification solutions. The market in Rest Of Europe is supported by a robust healthcare infrastructure, growing government funding for life sciences research, and expanding collaborations between academic centers and industry players.
- Rest Of Europe's regulatory environment continues to evolve favorably for cell-based therapies, encouraging both established manufacturers and emerging innovators to strengthen their market presence.
- Between 2026 and 2031, Rest Of Europe is expected to see accelerated adoption of automated and high-throughput cell isolation systems, driven by the region's commitment to advancing cellular medicine and biotechnology capabilities..
Key Market Statistics
- CAGR (2026-2031) 9.0% CAGR
- Market Size, 2026 ~USD 120.2 Million
- Forecast, 2031 ~USD 184.9 Million
- Country Rest Of Europe
Rest Of Europe Cell Isolation Market Overview
Market Valuation Growth :
Rest Of Europe's cell isolation market is valued at USD 120.2 million in 2026, with projections reaching USD 184.9 million by 2031, representing a robust 9.0% CAGR over the forecast period.
Regional Technology Adoption :
Advanced cell isolation technologies are increasingly adopted across Rest Of Europe's research institutions, clinical laboratories, and biopharmaceutical companies, driving market expansion and innovation.
Growth Drivers :
Increasing investment in regenerative medicine, rising demand for personalized medicine, and expanding stem cell research initiatives across Rest Of Europe are key catalysts for market growth.
Competitive Landscape :
Rest Of Europe's cell isolation market features a mix of established European players and emerging biotech companies competing through technological advancement and strategic partnerships.
Rest Of Europe Cell Isolation Market Dynamics
- The 9.0% CAGR reflects increasing adoption of sophisticated isolation technologies in academic institutions and commercial laboratories, supported by rising healthcare investments and regulatory support for advanced therapies. The forecast period through 2031 indicates sustained growth momentum as Rest Of Europe strengthens its position in regenerative medicine and cell-based therapeutics.
- Emerging markets within the region, coupled with collaborative research initiatives and improved reimbursement frameworks, are expected to accelerate market penetration and create new opportunities for technology providers and service providers..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Rest Of Europe's cell isolation market will grow from USD 120.2 million in 2026 to USD 184.9 million by 2031, representing a 9.0% CAGR.
- Rest Of Europe is witnessing increased demand for cell isolation technologies driven by expanding cell therapy and regenerative medicine research programs.
- Rest Of Europe's market growth is supported by strong government funding, academic-industry partnerships, and favorable regulatory frameworks for cell-based therapeutics.
- Rest Of Europe is expected to adopt more automated and high-throughput cell isolation systems as biopharmaceutical companies scale manufacturing capabilities through 2031.
Cell Isolation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SURFACE MARKER-BASED CELL ISOLATION (Technique) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 12.7% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 4.38 (2026) |
| Revenue Forecast (Billions) | ~USD 7.97 (2031) |
| Segments Covered | Product, Type, Cell Type, Cell Source, Technique |
Rest Of Europe Cell Isolation Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Type
- Beads
- Differentiated Cells
- Disposables
- Media & Sera
- Reagents & Kits
- Stem Cells
By Cell Type
- Animal Cells
- Human Cells
By Cell Source
- Adipose Tissue
- Blood & Blood-Derived Samples
- Bone Marrow
- Cord Blood/ Embryonic Stem Cells
- Other Cell Sources
By Technique
- Centrifugation-Based Cell Isolation
- Filtration-Based Cell Isolation
- Microfluidics & Label-Free Cell Isolation
- Surface Marker-Based Cell Isolation
Target Audience
- Biopharmaceutical Companies : Rest Of Europe-based and international biotech firms need regional market data to assess cell isolation technology adoption, identify partnership opportunities, and plan R&D investments across the region.
- Medical Device Manufacturers : Cell isolation equipment and consumables providers require Rest Of Europe-specific market intelligence to understand demand patterns, competitive positioning, and growth opportunities in clinical and research segments.
- Research Institutions & Universities : Academic centers and research organizations across Rest Of Europe need market insights to benchmark their capabilities, identify emerging technologies, and secure funding for cell isolation research initiatives.
- Clinical Laboratory Operators : Diagnostic and clinical laboratory networks in Rest Of Europe require regional market data to evaluate cell isolation technology investments, assess competitive threats, and optimize service offerings.
- Healthcare Investors & Consultants : Investment firms and management consultants focused on Rest Of Europe's healthcare sector need accurate market sizing and growth forecasts to support due diligence, valuations, and strategic advisory services.
Key Companies in the Rest Of Europe Cell Isolation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler system and reagents,Custom and collaborative programs (USPS BDS, TB, Ebola, new molecular tests), |
| MAXCYTE, INC | United States | Public Company | ExPERT STx and GTx flow electroporation instruments,ExPERT ATx and VLx instruments,Disposable processing assemblies (PAs), |
| GENERAL ELECTRIC | United States | Public Company | Commercial Engines & Services,Defense & Propulsion Technologies, |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use),Life Sciences tools and genomics,Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (oncology, neurology, fertility, rare diseases, cardiovascular, metabolic),Electronics (semiconductor and display materials, specialty gases, delivery equipment), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, catheters, sharps, vascular care),Connected Care (infusion, dispensing, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, pharma solutions), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical instruments and process analytics,Lab products and services (filtration, water systems, weighing, pipettes, microbiological testing), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research and Bioprocess, |
| QIAGEN | Netherlands | Public Company | Sample technologies (nucleic acid purification & stabilization),Molecular diagnostics assays (immune response, oncology, SRH, viral load),PCR & dPCR instruments and reagents, |
| REVVITY | United States | Public Company | Diagnostics instruments and automation platforms,Diagnostics reagents, assays, and kits,Life science research tools and genomic workflow solutions, |
| CORNING INCORPORATED | United States | Public Company | Optical Communications (fiber, cable, hardware, components),Display Glass Substrates (LCD, OLED),Specialty Materials (mobile, semiconductor optics, defense, radiation shielding, sunglasses), |
| LONZA | Switzerland | Public Company | Integrated Biologics (mammalian and drug product platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs and bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| BIO-TECHNE | United States | Public Company | Protein Sciences (reagents and proteomic tools),Diagnostics (controls, calibrators, assays, process controls),Spatial Biology and Genomics, |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
CEPHEID INC.
Cepheid Inc. is a United States-based private company founded in 1996 with 1,700 employees. The company develops molecular diagnostics and point-of-care testing solutions.
MAXCYTE, INC
MaxCyte, Inc. is a publicly traded United States company founded in 1998 with 91 employees. The company develops cell engineering technologies and platforms.
GENERAL ELECTRIC
General Electric is a publicly traded United States conglomerate founded in 1892 with 57,000 employees. The company operates across multiple industrial and technology sectors.
GE HEALTHCARE
GE Healthcare is a publicly traded United States company established in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
DANAHER CORPORATION
Danaher Corporation is a publicly traded United States company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses in life sciences, diagnostics, and environmental solutions.
MERCK KGAA
Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. The company operates in pharmaceuticals, life sciences, and performance materials.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a publicly traded United States company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a publicly traded United States company founded in 1897 with 72,000 employees. The company manufactures medical devices, laboratory equipment, and diagnostic products.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a publicly traded United States company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
SARTORIUS AG
Sartorius AG is a publicly traded German company founded in 1870 with 14,242 employees. The company manufactures laboratory and bioprocess equipment for pharmaceutical and biotechnology industries.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a publicly traded United States company founded in 1952 with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.
QIAGEN
QIAGEN is a publicly traded Netherlands-based company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and bioinformatics solutions.
REVVITY
Revvity is a publicly traded United States company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences research and diagnostics.
CORNING INCORPORATED
Corning Incorporated is a publicly traded United States company founded in 1851 with 67,200 employees. The company manufactures specialty glass, ceramics, and laboratory products.
LONZA
Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. The company provides contract manufacturing and life science solutions for pharmaceuticals and biotechnology.
BIO-TECHNE
Bio-Techne is a publicly traded United States company founded in 1976 with 3,100 employees. The company develops and manufactures proteins, antibodies, and reagents for life sciences research.
TERUMO CORPORATION
Terumo Corporation is a publicly traded Japanese company founded in 1921 with 30,591 employees. The company manufactures medical devices and blood management solutions.
Reasons to Buy this Report
- Regional Market Sizing : Obtain precise market valuation data specific to Rest Of Europe, including 2026 baseline (USD 120.2M) and 2031 forecasts (USD 184.9M), enabling accurate regional business planning and investment decisions.
- Growth Trajectory Analysis : Understand the 9.0% CAGR specific to Rest Of Europe and how it compares to global trends (12.7%), identifying regional opportunities and market maturity levels for strategic positioning.
- Sector-Specific Insights : Access detailed intelligence on cell isolation adoption across Rest Of Europe's research institutions, clinical laboratories, and biopharmaceutical companies to identify target customer segments.
- Competitive Intelligence : Gain insights into Rest Of Europe's competitive landscape, including key players, market consolidation trends, and differentiation strategies specific to the regional market dynamics.
- Investment & Expansion Strategy : Leverage Rest Of Europe-specific market data to develop informed go-to-market strategies, partnership opportunities, and expansion plans tailored to regional regulatory and commercial environments.
Frequently asked questions
What is the current size of the cell isolation market in Rest Of Europe?
Rest Of Europe's cell isolation market is valued at USD 120.2 million in 2026 and is projected to reach USD 184.9 million by 2031.
What is the expected growth rate for Rest Of Europe's cell isolation market?
Rest Of Europe's cell isolation market is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2026 to 2031.
What factors are driving growth in Rest Of Europe's cell isolation market?
Growth in Rest Of Europe is driven by increasing investments in regenerative medicine, cell therapy development, personalized medicine initiatives, government funding for life sciences research, and expanding academic-industry collaborations.
Which technologies are gaining traction in Rest Of Europe's cell isolation market?
Rest Of Europe is seeing accelerated adoption of automated and high-throughput cell isolation systems as biopharmaceutical companies scale manufacturing and research capabilities.
How does Rest Of Europe's regulatory environment support cell isolation market growth?
Rest Of Europe's regulatory framework is evolving favorably for cell-based therapies, encouraging both established manufacturers and emerging innovators to strengthen their market presence and invest in advanced isolation technologies.
RESEARCH METHODOLOGY
This research study extensively used secondary sources, directories, and databases to identify and collect information for analysis of the global cell isolation market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with primary research inputs to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the cell isolation market. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Stem Cell Society Singapore (SCSS), International Society for Advancement of Cytometry (ISAC), American Filtration and Separations Society (AFS), Food and Drug Administration (FDA), American Society for Cell Biology (ASC8), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Alliance for Regenerative Medicine (ARM). Secondary data were collected and analyzed to determine the overall size of the global cell isolation market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the cell isolation market. These methods were also used extensively to estimate the size of various market segments.
Cell Isolation Market/Cell Separation Market : Top-Down and Bottom-Up Approach
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Cell isolation is the process of separating specific cells from a given sample. It is a tool in biological research that enables the isolation of a single cell type from heterogeneous cell populations without contamination by other cell types. This process is widely used for the isolation of biomolecules to produce vaccines, drugs, antibodies, enzymes, proteins, and other biotechnology products.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Hospitals and diagnostic laboratories
- Market research & consulting firms
- Medical institutions & universities
Report Objectives
- To define, describe, and forecast the cell isolation market based on product, cell type, cell source, technique, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall cell isolation market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the cell isolation market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the cell isolation market
- To benchmark players within the cell isolation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy
Customization Options :
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe Cell Isolation Market, by country
- Further breakdown of the Rest of Asia Pacific Cell Isolation Market, by country
- Further breakdown of the Rest of Latin America Cell Isolation Market, by country
- Further breakdown of the Rest of Middle East Cell Isolation Market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Get the Full Cell Isolation Market Report
Full forecast, segment splits, and company analysis for all Cell Isolation Market.
- US Cell Isolation Market
- Canada Cell Isolation Market
- Germany Cell Isolation Market
- UK Cell Isolation Market
- France Cell Isolation Market
- Italy Cell Isolation Market
- Spain Cell Isolation Market
- China Cell Isolation Market
- Japan Cell Isolation Market
- India Cell Isolation Market
- Australia Cell Isolation Market
- South Korea Cell Isolation Market
- Brazil Cell Isolation Market
- Mexico Cell Isolation Market
- Saudi Arabia Cell Isolation Market
- UAE Cell Isolation Market
- Rest Of Asia Pacific Cell Isolation Market
- Rest Of Latin America Cell Isolation Market
- Rest Of GCC Countries Cell Isolation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report